"Citron's reports are a lot more fun to read than just about anything published by a mainstream Wall Street stock analyst."
-- Bloomberg News

Twitter
May 29, 2015
HomeReportsArchivesContact Us / SuggestionsLegal DisclaimerWho is Citron
 

Citron Chimes on Lumber Liquidators — Before You Short Down Here — Step Back and Read

Posted in Citron Reports by Stocklemon on the March 10th, 2015

Obviously Lumber Liquidators (NYSE:LL) has an image problem, but Citron believes the selloff is largely overdone here.  

The stock is off 60% from when its CEO first warned that an unfavorable 60 Minutes story was coming, but the reality is that the actions and advice of the California Air Resources Board ought to be considered and heeded by all investors.

So before piling on this short at these levels, perhaps a step back and rational reassessment would be a good idea. 

For the Full Commentary, Click Here

 

AXDX Big Lie Exposed by SEC — $1.00 Target within 18 Months

Posted in Citron Reports by Stocklemon on the March 9th, 2015

It is well known that Accelerate Diagnostics (NASDAQ:AXDX) is a controversial stock.  Here are the main reasons:

*   11 years of unfulfilled promises about the same product

*   No viable commercial product on the immediate horizon

*   Scant R&D

*   Technology rejected by two major pharma companies, who each had exclusive rights to AXDX's platform for months — and then walked away

*   Not a single independent scientific publication on its technology — despite over 30 papers authored by employees, and individuals compensated by the company

*   A competitive landscape increasingly crowded with high-credibility and well funded competitors, each aggressively bringing new technologies to market — many already FDA approved and/or Europe CE approval

Citron won't rehash previously published stories about his company's suspect past, but rather focus on the heart of what is new, unreported and publicly sourced.  We'll step you through the extraordinary sequence in which the SEC at its finest, forces the company to fess up and abandon its 10+ year misleading overreach of a story about rapid diagnostics using direct from patient blood samples.

This company's claim to innnovative medical diagnostic technology has been exposed by its own filings.  It is careening toward irrelevance without a viable product. 

 

For the Story You Won't Read Anywhere Else, Click Here

(As always, Citron recommends you download the PDF, then right-click to follow the links)

Next Page »


3 queries in 0.259 seconds